Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „erlotinib“
Suchtreffer
Begriffe & Kennungen
Cyramza · 4.8 · 13 Table 7: ADRs reported in patients treated with ramucirumab in combination with chemotherapy or erlotinib i
Eintrag öffnenCyramza · 4.8 · The most common adverse reactions observed in patients treated with ramucirumab in combination with erlotinib
Eintrag öffnenErlotinib Hydrochlorid
Eintrag öffnenGiotrif · 4.8 · GIOTRIF Erlotinib (40 mg/day) N = 392 N = 395 NCI-CTC Grade Any 3 4 Any 3 4 Grade Grade MedDRA Preferred Term
Eintrag öffnenLokelma · 4.5 · 4 saquinavir, raltegravir, ledipasvir and rilpivirine) and tyrosine kinase inhibitors (erlotinib, dasatinib an
Eintrag öffnenTarceva · 4.3 · Hypersensitivity to erlotinib or to any of the excipients listed in section 6.1.
Eintrag öffnenTarceva · 4.5 · Erlotinib and Capecitabine Capecitabine may increase erlotinib concentrations. When erlotinib was given in com
Eintrag öffnenTarceva · 4.5 · Erlotinib and Carboplatin/Paclitaxel Erlotinib increases platinum concentrations. In a clinical study, the con
Eintrag öffnenTarceva · 4.5 · Erlotinib and Gemcitabine In a Phase Ib study, there were no significant effects of gemcitabine on the pharmac
Eintrag öffnenTarceva · 4.5 · Erlotinib and P-glycoprotein inhibitors Erlotinib is a substrate for the P-glycoprotein active substance trans
Eintrag öffnenTarceva · 4.5 · Erlotinib and coumarin-derived anticoagulants Interaction with coumarin-derived anticoagulants including warfa
Eintrag öffnenTarceva · 4.5 · Erlotinib and medicinal products altering pH Erlotinib is characterised by a decrease in solubility at pH abov
Eintrag öffnenTarceva · 4.5 · Erlotinib and other CYP substrates Erlotinib is a potent inhibitor of CYP1A1, and a moderate inhibitor of CYP3
Eintrag öffnenTarceva · 4.5 · Erlotinib and proteasome inhibitors Due to the working mechanism, proteasome inhibitors including bortezomib m
Eintrag öffnenTarceva · 4.5 · Erlotinib and smokers Results of a pharmacokinetic interaction study indicated a significant 2.8-, 1.5- and 9-
Eintrag öffnenTarceva · 4.5 · Erlotinib and statins The combination of Tarceva and a statin may increase the potential for statin-induced my
Eintrag öffnenTarceva · 4.5 · Erlotinib is metabolised in the liver by the hepatic cytochromes in humans, primarily CYP3A4 and to a lesser e
Eintrag öffnenTarceva · 4.5 · Potent inducers of CYP3A4 activity increase erlotinib metabolism and significantly decrease erlotinib plasma c
Eintrag öffnenTarceva · 4.5 · Potent inhibitors of CYP3A4 activity decrease erlotinib metabolism and increase erlotinib plasma concentration
Eintrag öffnenTarceva · 4.5 · When erlotinib was co-administered with ciprofloxacin, a moderate CYP1A2 inhibitor, the erlotinib exposure [AU
Eintrag öffnen